NCT00165633终止2 期
A Randomized, Placebo-Controlled, Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 540
- 主要终点
- Relapse-free survival period.
研究概览
简要总结
The purpose of this study is to determine the superiority of inhibitory effects and safety of Menatetrenone (E0167) on recurrence in patients with hepatocellular carcinoma.
详细描述
The study was conducted as a multicenter, randomized, parallel, placebo-controlled, double-blind comparative clinical study. Patients were randomly assigned in a double-blind manner to receive 45 or 90 mg/day of oral vitamin K2 or an identical-appearing placebo. Study drug was administered orally three times daily after meals until recurrence.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •20 years or older at the time of obtaining consent.
- •Systemic conditions are 0 to 2 score of Performance Status (according to Eastern Cooperative Oncology Group: ECOG).
- •Diagnosis of hepatocellular carcinoma is based on the following 1) or 2).
- •Patients who are confirmed to have early tumor stain and typical finding(s) of hepatocellular carcinoma with CT or MRI imaging
- •Patients who underwent tumor biopsy and are histopathologically diagnosed as hepatocellular carcinoma
- •Primary onset or recurrence of hepatocellular carcinoma is not more than 1 time.
- •Patients who underwent the following 1) or 2) within 90 days prior to registration to determine therapeutic effect.
- •Patients who underwent local therapy to achieve complete hepatonecrosis and are confirmed to have complete hepatonecrosis with CT imaging or MRI.
- •Patients who underwent surgical treatment(s) and are confirmed not to have residual tumor with CT or MRI imaging.
- •Patients who meet the following items to determine liver function:
- •Albumin is 2.8 g/dL or above
- •Total bilirubin is under 2.0 mg/dL
- •Prothrombin activation is 40% or above
- •Patients who are given full explanation of study participation (including cancer notification) and submit written consent forms with their understanding as well as voluntary will for this study.
排除标准
- •Hepatocellular carcinoma:
- •Patients who have extrahepatic metastasis
- •Patients who have portal invasion
- •Patients who experienced with systemic administration of anti-malignant tumor drugs to treat hepatocellular carcinoma
- •Patients treated with transcatheter arterial chemoembolization (TAE) alone as a non-local therapy for hepatocellular carcinoma
- •- 1) Patients of (a) or (b) previously treated with interferon preparations (including clinical studies).
- •(a) Patients with chronic hepatitis C virus (HCV) showing HCV-RNA negative
- •(b) Patients with viral hepatitis treated with interferon preparations within the last 2 years (from the same day, 6 months earlier to the day of obtaining consent forms)
- •(c) Patients with encephalopathy in which pharmacotherapy is ineffective
- •(d) Patients with ascites or pleural effusion that cannot be managed with diuretics
- •Systemic conditions:
- •Patients unable to receive oral administration
- •Patients with a history of gastrectomy or extensive resection of digestive tract
- •Patients who are suspected to have biliary occlusion, choleretic disorder, cholecystectomy, or malabsorption of liposoluble agents
- •Patients with complicated serious diseases such as cardiovascular (e.g., myocardial infarction), hematological (e.g., aplastic anemia), and/or renal dysfunctions (e.g., acute and chronic renal failure)
- •Patients with multiple cancers (within a 5-year cancer-free period [from the same day of 5 years earlier to the day of obtaining consent forms])
- •Drug administration:
- •Patients on warfarin potassium therapy
- •Patients with a known history of drug allergy to E0167 or its ingredients
- •Patients who received vitamin K preparations within the recent 6 months (from the same day of 6 month earlier to the day of obtaining consent forms)
- •Other exclusion criteria
- •Women of pregnant, lactating, childbearing potential, or with the intention of becoming pregnant
- •Patients who are presently participating in another clinical study (except for follow-up surveys for study outcomes)
- •Patients who are judged to be ineligible for study entry by the investigator or subinvestigator
研究组 & 干预措施
1
Experimental
干预措施: Menatetrenone (Drug)
2
Experimental
干预措施: Menatetrenone (Drug)
3
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Relapse-free survival period.
时间窗: Every 3 months
次要结局
未报告次要终点
研究者
相似试验
已完成
2 期
A Study to Evaluate the Use of Memantine In Combination With Anti-HIV Drugs to Treat AIDS Dementia Complex (ADC)AIDS Dementia ComplexHIV InfectionsNCT00000867National Institute of Allergy and Infectious Diseases (NIAID)120
招募中
2 期
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated CardiomyopathyNon-ischemic Dilated CardiomyopathyNCT04476901Joshua M Hare136
已完成
2 期
MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)SchizophreniaParanoid SchizophreniaNCT00482430Merck Sharp & Dohme LLC50
已完成
3 期
Evaluation of Effectiveness and Safety of Paliperidone ER (Extended-release) Compared With Quetiapine in Patients With SchizophreniaSchizophreniaNCT00334126Johnson & Johnson Pharmaceutical Research & Development, L.L.C.399
尚未招募
1 期
Safety, Tolerability, Pharmacokinetics and Efficacy Study of HS-10380 in Patients With SchizophreniaSchizophreniaNCT05964790Jiangsu Hansoh Pharmaceutical Co., Ltd.112